Figure 9.

PKC-β inhibition prevents Akt S473 phosphorylation in diabetic kidneys. Type 1 diabetic (mRen-2)27 rat kidney cortex was analyzed 12 wk after onset of diabetes. A group was treated with the PKC-β inhibitor ruboxistaurin. (A and B) Western blots of cortical protein demonstrate a significant increase in Akt S473 phosphorylation in diabetics, prevented by ruboxistaurin (n = 8; *P < 0.05 STZ versus others). Akt T308 phosphorylation, however, was unaffected by treatment with ruboxistaurin. (C) Immunofluorescence of cortical sections demonstrates an increase in pAkt S473 (green) in glomeruli, which are identified by staining for the MC marker Thy 1.1 (red). Areas of overlap appear as yellow.